Trial Comparing Outcomes With Merocel Packing or Thrombin-JMI for Anterior Epistaxis
Status:
Terminated
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
Epistaxis is a common problem among people of all ages and backgrounds. However, occasionally
epistaxis can be severe enough to require emergency room admission. Among the treatment
options for epistaxis, nasal packing is the most common approach. This approach requires a
return visit to the clinic for removal of the packing. Additionally, there is a great deal of
pain during the insertion and removal of this packing. This study aims to justify the further
investigation of thrombin as a potential treatment approach for these patients. Thrombin
could provide a treatment approach that reduces pain and eliminates the need for a return
visit to the clinic.
Phase:
N/A
Details
Lead Sponsor:
University of Kansas Medical Center
Collaborator:
King Pharmaceuticals is now a wholly owned subsidiary of Pfizer